This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.

This research is an experimental study with a randomized controlled clinical design involving two intervention groups: one receiving secretome injections and the other receiving intradermal platelet-rich plasma injections. Evaluations are conducted by measuring hair density and the terminal-to-vellus hair ratio before and after treatment using trichoscopy/dermoscopy.

Inclusion Criteria:

• Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
• Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
• Female patients who are not currently pregnant or breastfeeding.
• Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
• Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
• Patients who are proficient in Indonesian and willing to provide written informed consent.

Exclusion Criteria:

• Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
• Patients presenting with types of hair loss other than androgenetic alopecia.
• Patients currently undergoing therapy with 5-alpha reductase inhibitors.
• Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
• Patients with active infections and/or active dermatitis on the scalp.
• Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
• History of hypertrophic scarring or blood clotting (coagulation) disorders.
• Patients unable to complete the research procedures in their entirety.